Journal
JOURNAL OF IMMUNOLOGY
Volume 175, Issue 2, Pages 1310-1319Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.175.2.1310
Keywords
-
Categories
Funding
- NCRR NIH HHS [RR 00425] Funding Source: Medline
- NEI NIH HHS [EY 008976, EY 011708] Funding Source: Medline
- NIDDK NIH HHS [DK 063121] Funding Source: Medline
Ask authors/readers for more resources
Human orbital fibroblasts exhibit a unique inflammatory phenotype. In the present study, we report that these fibroblasts, when treated with IL-1 beta, express high levels of IL-6, a cytokine involved in B cell activation and the regulation of adipocyte metabolism. The magnitude of this induction is considerably greater than that in dermal fibroblasts and involves up-regulation of IL-6 mRNA levels. IL-1 beta activates both p38 and ERK 1/2 components of the MAPK pathways. Disrupting these could attenuate the IL-6 induction. The up-regulation involves enhanced IL-6 gene promoter activity and retardation of IL-6 mRNA decay by IL-1 beta. Dexamethasone completely blocked the effect of IL-1 beta on IL-6 expression. Orbital fibroblasts also express higher levels of IL-6R than do skin-derived cells. When treated with rIL-6 (10 ng/ml), STAT3 is transiently phosphorylated. Thus, the exaggerated capacity of orbital fibroblasts to express high levels of both IL-6 and its receptor in an anatomic site-selective manner could represent an important basis for immune responses localized to the orbit in Graves' disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available